

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Grygiel Nancy A.</u>  (Last) (First) (Middle) ONE AMGEN CENTER DRIVE  (Street) THOUSAND CA 91320 OAKS  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/24/2020	3. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC [ AMGN ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) SVP & CCO	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,142 <sup>(1)(2)</sup>	D	
Common Stock	88.786 <sup>(3)</sup>	I	401(k) Plan

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Nqso (Right to Buy)	05/01/2019 <sup>(4)</sup>	05/01/2027	Common Stock 4,139	162.6	D	
Nqso (Right to Buy)	04/27/2020 <sup>(5)</sup>	04/27/2028	Common Stock 3,470	177.46	D	
Nqso (Right to Buy)	05/03/2021 <sup>(6)</sup>	05/03/2029	Common Stock 3,948	177.31	D	
Nqso (Right to Buy)	05/05/2022 <sup>(7)</sup>	05/05/2030	Common Stock 3,542	236.36	D	

**Explanation of Responses:**

- These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 748 RSUs which fully vest on 8/1/2020; 159 RSUs which fully vest on 5/1/2021; 302 RSUs which vest in two installments of 149 on 4/27/2021 and 153 on 4/27/2022; 452 RSUs which vest in two installments of 149 on 5/3/2021 and 5/3/2022 and one installment of 154 on 5/3/2023; and 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 142 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
- 2,731 of these non-qualified stock options have vested and are exercisable and 1,408 of these options will vest and become exercisable on 5/1/2021.
- 1,145 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,145 on 4/27/2021 and 1,180 on 4/27/2022.
- These non-qualified stock options will vest and become exercisable in three installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,343 on 5/3/2023.
- These non-qualified stock options will vest and become exercisable in three installments of 1,168 on 5/5/2022, 1,169 on 5/5/2023 and 1,205 on 5/5/2024.

/s/ Andrea A. Robinson,  
Attorney-in-Fact for Ms. Grygiel      06/30/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

Know all men by these presents, that the undersigned hereby constitutes and appoints each of Dennis Yai and Andrea A. Robinson, signing singly, the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, as may be required as a result of the undersigned's position as an officer and/or director of Amgen Inc. (the "Company").

The undersigned hereby grants to each such attorney-in-fact full power and authority to execute such Forms 3, 4 and 5 as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of June, 2020.

/s/ Nancy A. Grygiel  
Name: Nancy A. Grygiel